Archive | 2021
Interluquina-6 como biomarcador de éxito de tratamientos para tratornos temporomandibulares articulares
Abstract
Objective: To evaluate IL-6 level changes in synovial fluid (SF) in the temporomandibular joint (TMJ) post-treatment of temporomandibular disorders (TMD).\xa0\xa0 Material and Methods:\xa0 In a first search, MeSH terms were used in Pubmed. A second one was conducted in Pubmed and the Cochrane Library, with MeSH terms and keywords in an advanced search. Inclusion criteria were all systematic reviews since 2015 on treatments for TMD, and clinical studies since 2015 where IL-6 levels were measured in SF post-treatment of TMD. Exclusion criteria were all studies where IL-6 levels were measured in plasma or joint tissue. Results: In the first search ,\xa0 41 results were obtained per title and abstract, of which 15 systematic reviews remained meeting the inclusion criteria. In a second search, 35 results were obtained, of which 28 were excluded by title and abstract as they were not pertinent. After full reading, three randomized clinical studies remained that met the inclusion criteria.\xa0 Conclusion:\xa0 It is necessary to continue considering new therapeutic strategies to decrease levels of pro-inflammatory cytokines, where IL-6 might become a possible biomarker in TMD.